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Vascular Involvement in 
Rheumatoid Arthritis
Alexandru Caraba, Stela Iurciuc and Mircea Iurciuc
Abstract
Rheumatoid arthritis (RA) represents the one of the most common inflamma-
tory rheumatic diseases, which generates disability and significantly reduces the 
quality of life. RA can affect the vascular system, in addition to joint involvement. 
Vascular involvement increases the morbidity and mortality among these patients. 
Macrovascular disease, related to accelerated atherosclerosis, has a high prevalence 
among RA patients, in the form of carotid artery disease, ischemic heart disease, 
and peripheral arterial obstructive disease. Microvascular disease, studied in recent 
years by means of nailfold capillaroscopy, is present even in the early stage of RA 
evolution. Rheumatoid vasculitis can occur in severe forms of RA.
Keywords: macrovascular, microvascular involvement, rheumatoid arthritis
1. Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory disorder, characterized 
by synovitis of small- and medium-sized joints, which causes cartilage breakdown, 
bone erosions, and finally destruction and loss of joints function. But beside the 
joints involvement, RA, especially with long-term evolution and suboptimal control 
of the disease activity, can generate systemic involvement (cardiovascular, respira-
tory, haematologic) [1].
RA is the most common inflammatory rheumatic disease, affecting about 
0.5–1% of North American and European people over 18 years. The RA incidence 
and prevalence have regional differences: the lowest rates are identified in Southern 
regions, and the highest rates are present in Northern Europe and North America. 
Women are more frequently affected than men (women/men ratio 3/1), this disease 
occurring more commonly in the 4th or the 5th decades of life [2, 3].
RA is an autoimmune disorder; through the interaction between genetic pre-
disposition and environmental factors, a trigger event generates an inflammatory 
autoimmune response, which affects primarily the synovial joint but also the blood 
vessels [1].
The interrelation between RA and vascular involvement began to be studied 
many years ago. In 2008, in their review, Szekanecz and Koch introduced the term 
“vascular rheumatology,” referring to vascular impairment from inflammatory 
rheumatic diseases [4]. Indeed, in RA, vascular involvement comprises both macro- 
and microvessels. Special attention requires rheumatoid vasculitis, a rare but severe 
complication of this disease. Histologically, vascular lesions have been found in 25% 
of RA patients [5]. Patients with RA are prone to early and accelerated atherosclero-
sis, which induces higher cardiovascular risk, independent of traditional risk factors 
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(diabetes mellitus, arterial hypertension, smoking, dyslipidemia, age, lifestyle). 
RA-related risk factors are identified and characterized in these patients [6, 7]. In 
RA patients, the cardiovascular risk is obtained by the multiplication of measured 
risk (SCORE, Framingham) by a factor of 1.5, if two of the three following criteria 
are fulfilled (RA evolution >10 years, positivity of RF or ACPA, extra-articular 
involvement) [8].
2. Risk factors for vascular involvement
Vascular involvement in RA patients has a multifactorial model. Traditional 
cardiovascular risk factors together with those related to RA contribute to the devel-
opment of macro- and microvascular involvement. It is known that the first step in 
atherogenesis development is endothelial dysfunction. Several factors associated 
with RA are involved in the endothelial dysfunction appearance: pro-inflammatory 
mediators and cells, oxidative stress, insulin resistance, physical inactivity, genetic 
factors, and drugs [9].
During its evolution, RA is a chronic inflammatory condition. Even in the pre-
clinical stage, then continuing with the period when the clinical picture is complete, 
the chronic inflammatory environment exists in these patients. Pro-inflammatory 
cytokines contribute to synovial inflammation and to atherosclerosis development, 
through endothelial dysfunction.
Under physiological conditions, endothelium represents an active barrier 
between vascular wall and bloodstream, being involved in maintaining vascular 
muscle tone and homeostasis, controlling cell adhesion, proliferation, and coagula-
tion balance. In pathophysiological conditions (chronic inflammatory diseases), 
these endothelium physiological functions are disturbed, and endothelial dysfunc-
tion occurs. During this new situation, reduced vasodilation, pro-inflammatory 
and prothrombotic status, and increased cell adhesion and proliferation contribute 
to atherosclerosis development. Endothelial dysfunction is a preclinical marker 
of atherosclerosis development, commonly detected in RA patients, but it is also 
involved in plaque progression and the occurrence of atherosclerotic complications 
[10, 11]. In RA patients, endothelial dysfunction occurs differentially in different 
vascular beds (macro- and microcirculation) [12]. Bocci et al. showed that in RA 
patients, the coronary microvascular involvement is identified in the absence of 
macrovascular disease [13].
Several factors are involved in endothelial dysfunction appearance in RA 
patients (Table 1) [9, 11].
2.1 Arterial hypertension
High blood pressure represents an independent predictor of cardiovascular events 
in RA patients. COMORA study reported that the prevalence of high blood pres-
sure among RA patients was about 40% [14]. In their meta-analysis, Baghdadi et al. 
reported that high blood pressure was associated with a relative risk of cardiovascular 
morbidity of 2.24 in patients with RA [15]. On the other hand, Panoulas et al. identi-
fied that the most important determinant of target organ damage in RA patients is 
arterial hypertension [16]. It is known that the increase in systolic blood pressure with 
20 mmHg is associated with high risk of endothelial dysfunction and cardiovascular 
disease. Some drugs used in RA therapy, as Leflunomide, NSAIDs, corticoids, and 
cyclosporine, are associated with high risk of arterial hypertension development, 
with consecutive endothelial dysfunction [7]. In hypertensive RA patients, ambula-
tory blood pressure monitoring revealed that the non-dipper and excessive dipper 
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patterns were frequent among them and pulse pressure was increased, these charac-
teristics predisposing to cardiovascular complications [17]. Most researchers won-
dered if high blood pressure is effectively controlled in RA patients. Panoulas et al. 
and Desai et al., in their studies, showed that the identification and effective control 
of high blood pressure is suboptimal in RA patients [18, 19]. Two studies published 
in 2016 and one published in 2019 showed that there were no significant differences 
in the diagnosis and therapy of high blood pressure in RA patients versus the general 
population [20–22].
2.2 Dyslipidemia
Dyslipidemia represents a well-known traditional cardiovascular risk factor, 
affecting between 55 and 65% of the RA patients [23]. These patients present low 
levels of low density lipoprotein (LDL), high density lipoprotein (HDL), and total 
cholesterol, these levels being inversely correlated with markers of inflamma-
tion. But during inflammation, these molecules develop functional and structural 
changes, becoming atherogenic and promoting endothelial dysfunction. Some 
drugs used in RA treatment may increase lipid levels: DMARDs, TNF-α inhibitors, 
tocilizumab, and IL-6 receptor blocker [8].
2.3 Insulin resistance and metabolic syndrome
The prevalence of insulin resistance and metabolic syndrome is increased in 
RA patients (40%), increasing the risk of endothelial dysfunction and cardiovas-
cular events by twofold compared to the general population. RA with high activ-
ity increases the effect of insulin resistance/metabolic syndrome on endothelial 
dysfunction. The effect of the medication that decreases the RA activity (DMARDs, 
biologics) on insulin resistance is not to be neglected. Endothelial-dependent vaso-
dilation, mediated by nitric oxide release, is impaired in insulin resistance individu-
als. They display high levels of endothelin and plasminogen activator inhibitor in 
plasma [8].
2.4 Obesity
Obesity, physical inactivity, and endothelial dysfunction coexist in RA patients. 
Obesity is associated with other cardiovascular risk factors, as atherogenic dyslipid-
emia, high blood pressure, insulin resistance, and low grade inflammation, gen-
erating endothelial dysfunction. But in RA an association between low body mass 
Traditional risk factors
• Arterial hypertension
• Dyslipidemia
• Insulin resistance and metabolic syndrome
• Obesity
• Smoking
RA-related factors
• Chronic inflammatory status
• Oxidative stress
Table 1. 
Factors involved in RA endothelial dysfunction.
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(secondary to high rheumatoid inflammation, generating rheumatoid cachexia) 
and cardiovascular events, too, is described [8].
2.5 Smoking
Another cardiovascular risk factor, smoking, is involved in RA appearance [24]. 
Rojas-Serrano et al. showed that the RA patients who smoked had a more severe RA 
evolution and positivity for rheumatoid factor and anticitrullinated protein anti-
bodies [25]. Baghdadi et al. demonstrated that the cardiovascular risk was higher in 
RA patients who smoked [15].
Baghdadi et al. revealed in their meta-analysis that in RA patients the increased 
cardiovascular morbidity is related to the presence of high blood pressure [relative 
risk (RR): 2.24, 95% confidence intervals (CI): 1.42–3.06], smoking (RR: 1.5, 95%  
CI: 1.15–1.84), obesity (RR: 1.16, 95% CI: 1.03–1.29), insulin resistance (RR: 1.94, 
95% CI: 1.58–2.30), and atherogenic dyslipidemia (RR: 1.73, 95% CI: 1.03–2.44) [15].
2.6 Inflammation
Chronic inflammation is considered to be an independent risk factor for the 
atherosclerosis development. Together with immune dysregulation, it contributes 
to endothelial dysfunction and atheroma plaque development. The cardiovascular 
risk begins to be evident from the early stages of RA, making the cardiovascular 
investigation necessary even from the first medical visit [26].
Chronic inflammation is considered to be of utmost importance in endothe-
lial dysfunction onset. The previous studies have shown that the inflammatory 
processes in the rheumatoid synovium and atherosclerotic plaques are remark-
ably similar. TNF-alpha, interleukin-1 (IL-1), and interleukin-6 (IL-6) play an 
important role in RA pathogenesis, but they are involved in the development of 
endothelial dysfunction, too. TNF-alpha increases IL-1, IL-6, IL-8, and chemokines 
synthesis. On the other hand, this cytokine increases cellular infiltration in the 
synovium, through enhancing chemokine expression, endothelial cells activation, 
and neoangiogenesis. IL-1 stimulates the expression of adhesion molecules on the 
endothelial cells and neoangiogenesis. IL-6 contributes to endothelial cell activa-
tion; upregulates the expression of the chemokines that attract T cells, leading to 
enhanced cellular infiltration; and increases the concentration of VEGF with high 
vascular permeability appearance. VEGF induces the endothelial cell activation and 
differentiation, generating neoangiogenesis, too. These cytokines have metabolic 
effects, acting on the adipose tissue, the skeletal muscle, and the liver and contrib-
uting to the traditional cardiovascular risk factor production (insulin resistance, 
obesity). They contribute to the endothelial dysfunction development.
The inflammatory environment increases the effect of traditional cardiovascular 
risk factors on endothelial cells, generating endothelial dysfunction development. 
Other studies revealed that the anti-inflammatory treatment improves the endothe-
lial dysfunction in RA patients [8, 27, 28].
2.7 Reactive oxygen species
Reactive oxygen species (ROS), generated at higher concentrations at sites of 
inflammation, can induce cellular injury. Vascular endothelial cells represent the 
main target for the ROS, increasing the endothelial permeability and promoting 
leukocyte adhesion. On the other hand, high levels of ROS and low levels of antioxi-
dants in RA with high inflammatory activity generate the impairment of the HDL 
5Vascular Involvement in Rheumatoid Arthritis
DOI: http://dx.doi.org/10.5772/intechopen.91142
function. Through these effects, ROS contributes to the endothelial dysfunction 
appearance in RA patients [7, 10].
2.8 RA treatment and vascular dysfunction
The drugs used in RA therapy may contribute to vascular dysfunction and 
cardiovascular risk.
Nonsteroidal anti-inflammatory drugs (NSAIDs) represent a class of drugs 
frequently used by these patients. The data regarding the NSAID use and cardio-
vascular risk in RA patients remain controversial. Data from the Danish nationwide 
registry revealed that the increased cardiovascular risk related to the overall use 
of NSAIDs in RA patients was modest and even significantly lower than in non-
RA subjects. Rofecoxib and diclofenac were the exception, being associated with 
increased cardiovascular risk [29]. It is recommended to use NSAIDs with caution 
in RA patients in the presence of cardiovascular risk factors or in the presence of 
ischemic cardiovascular disease [8, 9].
Corticosteroids contribute to insulin resistance, high blood pressure, and 
atherogenic dyslipidemia; all these factors are associated with endothelial dysfunc-
tion and subsequently appearance of cardiovascular events. But, on the other hand, 
by controlling inflammation, corticoids may reduce cardiovascular risk in RA 
patients. EULAR recommended the corticoid use at lowest dose possible (<7.5 mg 
Prednisone/day), for the shortest period of time [9].
Among disease-modifying drugs (DMARDs), methotrexate, sulfasalazine, and 
hydroxychloroquine are associated with the cardiovascular risk reduction. By con-
trolling inflammation (decrease of pro-inflammatory cytokine level), methotrexate 
improves the endothelial function in RA patients. But this drug contributes to 
endothelial protection by means of induction of AMPK-regulated protective genes. 
Sulfasalazine interferes with platelet function. Hydroxychloroquine improves 
lipid profile and has antithrombotic effects, thus reducing the cardiovascular risk. 
Leflunomide and cyclosporine are associated with arterial hypertension.
By using biologics (anti-TNF-alpha, anti-CD28, anti-CD20, anti-IL 6, anti-IL1), 
cardiovascular risk was reduced comparatively with the RA patients without this 
therapy.
Anti-TNF-alpha therapy improves endothelial function by means of inflamma-
tion reduction. It is important to know that the reduction in cardiovascular risk was 
recorded only in patients responsive to anti-TNF-alpha treatment.
Anti-IL-6 therapy improves endothelial function (measured by means of 
flow-mediated vasodilation) very early during the treatment. This effect is deter-
mined by reducing inflammation, although total cholesterol, LDL-cholesterol, and 
triglyceride levels are increased.
Anti-CD20 therapy reduces RA activity and has favorable effects on lipid profile, 
reducing endothelial dysfunction.
The use of abatacept in RA treatment has generated conflicting data regarding 
vascular dysfunction. Tofacitinib increases total cholesterol levels but without 
change of atherogenic index. This new drug was associated with low rates of cardio-
vascular events in RA patients [1, 8].
3. Macro- and microvascular endothelial dysfunction
All these factors contribute to disruption of vascular environment at the macro- 
and microcirculation levels, occurring endothelial dysfunction [2, 7].
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Macrovascular and microvascular endothelial dysfunction is identified in RA 
patients, not associated with each other, increasing cardiovascular risk in these 
patients [30]. The studies revealed a weak correlation between microvascular and 
macrovascular endothelial dysfunction in RA patients. Microvascular endothelial 
dysfunction results from the interaction between inflammation, immune dys-
regulation, and traditional cardiovascular risk factors, representing a significant 
factor related to accelerated atherosclerosis and future cardiovascular events in RA 
patients [31].
Structural and functional assessment of vasculature in RA patients uses differ-
ent methods (Table 2). It is known that the functional and morphological vascular 
changes may coexist, especially in the early atherosclerosis [27].
4. Macrovascular involvement in RA
Endothelial dysfunction is present in RA patients compared to healthy con-
trols. Although not all studies have shown the connection between endothelial 
 dysfunction and inflammation, the use of specific RA medication (especially 
 anti-TNF-alpha) has improved endothelial function in RA patients [32].
Arterial stiffness is increased in RA patients compared with controls, but an 
association between arterial stiffness and disease activity was not highlighted 
[27, 32].
Most studies identified that the cIMT was increased in RA patients, even in cases 
with newly established diagnosis. cIMT increases with the disease duration but is 
well known that the increase of cIMT is associated with the age of patients. The 
most studies did not reveal a consistent link between inflammation and vascular 
parameters. Van Zanten et al. explained that the long-standing, not current inflam-
mation has had vascular impact in RA patients [33]. Carotid plaque (Figure 1) is 
common findings among RA patients. Roman et al. reported that the carotid plaque 
was three times more prevalent in RA patients than in controls [34]. Dessein et al. 
identified that the 31% of RA patients had carotid plaque [35]. Another study, 
performed by Pope et al., reported a prevalence of carotid atherosclerotic plaque 
about 35% in RA patients [36]. Protogerou et al. highlighted the importance of 
carotid ultrasonography associated with the femoral one in RA cardiovascular risk 
assessment [37].
Plaque rupture leads to the occurrence of clinical events. The risk of plaque 
rupture is determined by its composition (calcification, lipid-rich necrotic core, 
neovascularization, inflammatory cell infiltration) and, on the other hand, by the 
Morphological assessment
Conducting artery Carotid intima-media thickness (cIMT)
Capillaries Nailfold capillaroscopy
Functional assessment
Conduit artery Pulse wave velocity (PWV)
Pulse wave analysis (PWA)
Flow-mediated dilation (FMD)
Nitroglycerin-mediated dilation (NMD)
Arterioles Laser Doppler imaging with iontophoresis
Venous occlusion plethysmography
Table 2. 
Methods for morphologic and functional vascular assessment.
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presence of inflammation. Pro-inflammatory cytokines (IL-6, TNF-alpha) are related 
to plaque progression and the appearance of complications [32, 35]. Skeoch et al. 
demonstrated in their study the increased prevalence of atherosclerosis in RA, pro-
viding data to confirm that atheroma plaques are at high risk of complications [38].
Ruscitti et al. have shown increased incidence and prevalence of subclinical and 
clinical atherosclerosis in RA patients, but reaching and maintaining remission had 
positive effect on the atherogenesis development [39].
Further longitudinal studies are necessary in order to characterize the acceler-
ated atherosclerosis in RA patients [32].
5. Microvascular involvement in RA
Yki-Jarvinen et al. studied the microvascular endothelial function in RA patients, 
using intrabrachial artery infusions of acetylcholine (endothelium dependent vasodi-
lation) and sodium nitroprusside (endothelium independent vasodilation). The 
authors concluded that the basal blood flow was increased, correlated with the degree 
of RA inflammatory activity and more inhibited by NG-monomethyl-L-arginine, 
suggesting that the responsiveness to nitric oxide was reduced [40]. In another study, 
Galarraga et al. identified that the systemic inflammation (evaluated by serum levels 
of C-reactive protein) was independently associated with microvascular dysfunction 
in RA patients [41]. Studying 65 RA patients and 40 healthy controls, Arosio et al. 
showed that the RA patients presented impaired microcirculatory reactivity, endo-
thelial dysfunction, and increased arterial stiffness. The authors concluded that these 
vascular alterations would be the link between RA and cardiovascular morbidity 
and mortality [42]. Endothelial dysfunction in RA patients was associated with high 
values of C-reactive protein and inducible nitric oxide synthase [43].
Microvascular morphological assessment may be performed by nailfold capilla-
roscopy, a noninvasive and repeatable method. By using this method, the following 
parameters are evaluated: tortuosity, loop size, density, angiogenesis, capillary loss, 
microbleeding, subpapillary venous plexus, and architectural structure [44].
Figure 1. 
Common carotid artery: Ultrasonography (increased cIMT and plaques in a long-standing RA evolution; 
personal collection).
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McGill and Gow studied by nailfold capillaroscopy the microvascular changes 
in patients with systemic sclerosis (10 pts.), systemic lupus erythematosus (9 pts.), 
and rheumatoid arthritis (11 pts.). They reported that the nailfold capillaroscopy 
had a specificity of 89% and a sensitivity of 80% in the differentiation of the 
capillaroscopic models of these three diseases [45]. In another study, performed 
by Altomonte et al., the authors identified that in RA patients the common capil-
laroscopic changes were represented by elongation and capillary tortuosity. Besides 
them, the visibility of the subpapillary venous plexus was correlated with the 
endothelial dysfunction [46]. In the study performed on 80 RA patients and 30 
healthy controls, Kuryliszyn-Moskal identified a significant correlation between 
soluble CD4 levels and the capillaroscopy findings [47].
In present, it is considered that there is no specific capillaroscopic model for 
RA [48]. Elongated and tiny loops, microhemorrhages, capillary low density, and 
subpapillary venous plexus visibility are common among RA patients [5].
Microvascular involvement appears early in the RA evolution. In their study, 
Scardina and Messina revealed that in patients with early RA, labial mucosa 
 capillaries presented alterations, as: elongation, decreased capillaries caliber com-
pared to healthy subjects. The authors suggested that the microvascular alterations 
could be extremely important in the diagnosis of suspected RA patients [5].
In their article, Lin et al. presented that in RA, the most common findings 
were represented by elongated and tiny capillaries and capillary tortuosity. The 
 subpapillary venous plexus was visualized in RA patients who had antinuclear anti-
bodies [44]. Sag et al. analyzed nailfold findings in 201 RA patients and 50 healthy 
controls. The authors examined the relationship between nailfold capillaroscopic 
findings and disease activity, expressed as DAS28. In 45.77% of RA patients, the 
authors identified nonspecific capillaroscopy findings: tortuosity, dilated capillar-
ies, and bushy capillaries. The association of Raynaud’s phenomenon increased the 
incidence of nailfold capillaroscopy abnormalities. No relation was found between 
microvascular abnormalities and RA activity score [49] (Figure 2).
Bernardino et al. identified mainly a non-scleroderma capillaroscopic pat-
tern in RA patients. The authors suggested that the microvascular abnormalities 
identified in RA patients represented the results of inflammation and endothelial 
dysfunction [50]. Cutolo et al. highlighted that in RA patients “scleroderma-like” 
capillaroscopic pattern may be found, especially in association with rheumatoid 
vasculitis [51].
Figure 2. 
Nailfold capillaroscopy (×200; subpapillary venous plexus visible, fragmentation of capillary blood circulation 
in patient with early RA; personal collection).
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6. Rheumatoid vasculitis
Rheumatoid vasculitis (RV) is the most serious extra-articular complication of 
RA with long-term evolution, generating high rates of morbidity and mortality (up 
to 40%, during 5 years) [52].
It can affect any organ or system, but the most frequent involved are the skin 
(nailfold lesions, palpable purpura, and leg ulcers) and peripheral nervous system 
(mononeuritis multiplex, distal symmetric sensory or sensorimotor neuropathy) 
[53–55].
Due to earlier diagnosis and new therapeutic strategies for RA, the prevalence of 
RV had progressively reduced over time. RV appears in RA patients with severe immu-
nological abnormalities, associating with other extra-articular manifestations [1].
RV is characterized by inflammation of small- and medium-sized arteries and 
capillaries. The risk factors associated with RV are represented by RA with pro-
longed evolution (> 10 years), rheumatoid nodules, males, smoking, seropositivity 
of rheumatoid factor, HLA-DRB1*0401/*0401, *0401/*0404, and *0101/*0401, 
HLA-C3 [55, 56].
RV can affect any organ or system of the body [1].
Clinical features of RV are cutaneous manifestations (digital infarcts, livedo 
reticularis, palpable purpura, ulcers, painful nodules, or even digital gangrene), 
peripheral nervous system manifestations (mononeuritis multiplex, distal symmet-
ric sensory or sensorimotor neuropathy), and internal organ manifestations (due 
to coronary, cerebral, mesenteric, renal artery involvement, much less common, 
but with significant morbidity and mortality). The patients with Felty’s syndrome 
develop more frequent RV [1, 54, 56].
Laboratory features of RV are represented by high levels of sedimentation rate 
and C-reactive protein, thrombocytosis, anemia, high levels of anti-cyclic citrul-
linated peptide antibodies and rheumatoid factor, and decreased levels of comple-
ment in patients with RV than the patients without this complication [1, 56, 57].
The RV diagnosis is easily established in the presence of cutaneous or nervous 
manifestations. Internal organ manifestations represent a challenge in establishing 
the correct RV diagnosis. Diagnosis confirmation is established by histopathological 
examination of the involved skin, muscle, nerve, or another affected organ [56].
In present, there are no guidelines for the RV treatment. Corticosteroids and 
cyclophosphamide have been used in severe, life-threatening cases of RV. In milder 
forms of RV, corticosteroids and methotrexate or azathioprine have been used. 
Rituximab and corticosteroids are preferred, due to higher efficiency and lower 
toxicity [55, 58, 59].
7. Conclusion
Vascular involvement in RA patients remains a chapter open to further research, 
in order to develop preventive measures, early diagnosis, and efficient therapy.
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